eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Special warnings and precautions for use

As with other anticoagulants, patients taking ELIQUIS are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. ELIQUIS administration should be discontinued if severe haemorrhage occurs.

Although treatment with ELIQUIS does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of ELIQUIS exposure may help to inform clinical decisions, e.g. overdose and emergency surgery.


See ELIQUIS SmPC for full prescribing information.

Diagnosemethoden

Stay on top of ELIQUIS product updates

Download guides designed for your patients

Access further resources, including treatment guidelines, patient materials and downloadable supporting materials


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

ALT = Alanine Transaminase   
aPTT = Activated Partial Thromboplastin Time   
AST = Aspartate Transaminase   
DVT = Deep Vein Thrombosis   
HIV = Human Immunodeficiency Virus   
INR = International Normalised Ratio   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
PT = Prothrombin Time   
ULN = Upper Limit of Normal

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.